Entegrion, a spinout from the University of North Carolina at Chapel Hill, has secured a $2 million appropriation from Congress for continued development of its blood coagulation technology.
Entegrion is developing a hemostatic agent it calls Stastix that would be used to control hemorrhages in wounds, trauma and surgical applications.
Earlier this year Entegrion closed on $3.7 million in venture financing.
Its first product, Stasilon, is a wound dressing. Entegrion hopes to begin selling Stasilon this year. Stasilon is a wound dressing.
In June, Entegrion received a “device listing” from the U.S. Food and Drug Administration. The listing will allow Entegrion to sell its product called AlphaBandage for use in treatment of external wounds.
Entegrion has worked with the Office of Naval research in developing its technology, which was licensed from both UNC and East Carolina University.
The company is focused on therapeutics to limit bleeding that results from combat trauma as well as other trauma, surgery and disease.
U.S. Senator Richard Burr and Congressmen David Price, Walter Jones and Howard Coble helped secure the funding, Entegrion said in a statement. The appropriation is the third that the company has received.
The company was known as Hemocellular Therapeutics when it was formed.
